Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and markets cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.
| Revenue (TTM) | 385 |
| Gross Profit (TTM) | $-36.22M |
| EBITDA | $-106.03M |
| Operating Margin | 0.00% |
| Return on Equity | -30.10% |
| Return on Assets | -17.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.01 |
| Price-to-Book | 0.80 |
| Price-to-Sales (TTM) | 1000000.00 |
| EV/Revenue | 1000000.0 |
| EV/EBITDA | 0.95 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $71.55M |
| Float | $60.44M |
| % Insiders | 4.88% |
| % Institutions | 80.66% |
Volatility is currently contracting
At 2 p.m. ET on Tuesday, June 30th, Nkarta President Nadir Mahmood will take part in a fireside at the H.C. Wainwright Cell Therapy Virtual Conference.
Enrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indications in Ntrust-1 and Ntrust-2 Regulatory agreement supports expansion into community-based settings with outpatient dosing to reduce patient burden Initial clinical data from Ntrust-1 and Ntrust-2 expected to be presented at a medical meeting in 2026 Cash balance of $266.7 million on March 31, 2026, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today reported financial results for the first quarter ended March 31, 2026.
Nkarta stock jumps after FDA backs protocol changes for ongoing NKX019 studies, enabling outpatient dosing and boosting study efficiency, patient access and commercial potential.
SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on key changes to the ongoing Ntrust-1 and Ntrust-2 clinical trials. The protocol amendments are designed to alleviate the need for overnight stays and reduce the overall burden on patients, enabling outpatient administration of NKX019 – an investigational CAR-NK cell therapy – by community research centers and community rheumatologists.
